firstwordpharma.com-pharma industry news and analysis

Données techniques du firstwordpharma.com

Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations. Notre service GeoIP a trouvé l'hôte firstwordpharma.com.Actuellement, hébergé dans France et son fournisseur de services est euNetworks Services GmbH .

Latitude:	43.296951293945
Longitude:	5.3810701370239
Pays:	France (fr)
Ville:	Marseille
Région:	Provence-Alpes-Cote d'Azur
ISP:	euNetworks Services GmbH

the related websites

domaine	Titre
firstwordpharma.com	pharma industry news and analysis - firstword pharma
jpn-news.com	world latest news & analysis
mic.com	mic \| breaking news, opinion, reviews, analysis
zdnet.com	technology news, analysis, comments and product reviews for it professionals \| z
sputniknews.com	sputnik international - breaking news & analysis - radio, photos, videos, infogr
garagedoorfixation.com	garage door repair industry news magazine articles for professional
huntscanlon.com	executive search and recruiting industry news \| hunt scanlon media
omaha.com	omaha.com \| breaking news, sports, entertainment and analysis from the omaha wor
poolgeniusnetwork.com	pool genius network - swimming pool industry news - information
harmonium-pharma.fr	harmonium pharma - radicati nel diabeteharmonium pharma
locksmithprofits.com	locksmith marketing ideas \| locksmith industry news & tools
khaleejtimes.com	khaleej times - dubai news, uae news, gulf, news, latest news, abu dhabi news, a
spinonews.com	technology news, science news, medical news, health news - spino news
gnome-help.org	stl news \| world news \| breaking news \| latest news \| today news
americascoop.com	home page \| visit americascoop news for latest news, breaking news, video news

aires-marines.fr

20minutes.fr

service-public.fr

Analyse d'en-tête HTTP

Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.

X-Powered-By:	PHP/5.2.17
Transfer-Encoding:	chunked
set-cookie:	TBMCookie_142828306924204467=472439001532119263dZb2JsR644tSkpckWQ9IhfztCxk=; path=/, ___utmvm=###########; path=/, SESS03909d8dd07980d982d468fc48cba91e=q79ufccaqps2e3qnh9nroupqi5; expires=Mon, 13-Aug-2018 00:14:23 GMT; path=/; domain=.firstwordpharma.com, anon_sid=q79ufccaqps2e3qnh9nroupqi5; expires=Tue, 20-Jul-2038 16:56:22 GMT
Expires:	Sun, 19 Nov 1978 05:00:00 GMT
Server:	Apache
Last-Modified:	Fri, 20 Jul 2018 20:41:03 GMT
Connection:	close
Cache-Control:	store, no-cache, must-revalidate, post-check=0, pre-check=0
Date:	Fri, 20 Jul 2018 20:41:03 GMT
Content-Type:	text/html; charset=utf-8

DNS

soa:	ns1.p16.dynect.net. hostmaster.pslgroup.com. 157 3600 600 604800 60
txt:	"v=spf1 include:_spf.google.com ~all" "v=spf1 a mx ip:84.207.240.152 ip:84.207.240.253 ip4:84.207.240.249 include:spf.intermedia.net ~all" "google-site-verification=Zn7g62Ocm0SnBFTnvPEvfnOScMr0a1_3GvHokqB9p8Y" "google-site-verification=grzMA-9vCQC4Pf7lZVgpgnTMG0PQ_AW8KWRHJ6DO6Uo"
ns:	ns4.p16.dynect.net. ns2.p16.dynect.net. ns3.p16.dynect.net. ns1.p16.dynect.net.
ipv4:	IP:84.207.240.117 ASN:13237 OWNER:LAMBDANET-AS European Backbone of AS13237, DE Country:DE
mx:	MX preference = 10, mail exchanger = aspmx2.googlemail.com. MX preference = 5, mail exchanger = alt2.aspmx.l.google.com. MX preference = 5, mail exchanger = alt1.aspmx.l.google.com. MX preference = 10, mail exchanger = aspmx3.googlemail.com. MX preference = 1, mail exchanger = aspmx.l.google.com.

HtmlToText

log in register friday, july 20, 2018 update! firstword is updating its privacy policy as of may 25, 2018 to reflect changes in global data protection and data privacy laws, including the gdpr in the european union. access policy here > home partner showcase register add colleague free trial contact us advertise my news my companywatch my conditionwatch my medicalmeetingwatch my productwatch my regulatorywatch my saved searches all news trending business company condition medical meeting product regulatory therapeutic category all insight, analysis and views viewpoints physician views kol views friday five analyst notes storywatch deals - alliances - financing fda adcom tracker focus on gene/car-t cell therapy focus on orphan drugs in the know market access issues where health meets tech emerging markets focus on biosimilars latest earnings reports product approvals channel mobile twitter rss podcasts radio -- don't miss ambitions in health: tech giants step up the pace as investment $$$ pour into digital health projects the scope and scale of tech giants ambitions in health become ever clearer. from drug discovery and clinical research to patient monitoring and disease management, tech giants are leveraging the latest advances in artificial intelligence (ai), deep learning, analytics and block chain technology to drive innovation and disruption. how can pharma respond and what strengths does it have that tech companies need? in this report, 15 digital health experts in pharma, consulting and tech companies to give a unique and comprehensive analysis of the current and future digital health landscape, the role leading technology companies will play and opportunities for pharma. find out more >> tags in today's news allergan amgen clinical research (r&d) corporate affairs dementia fda general practice gynaecology/obstetrics internal medicine isth leukaemias licensing lilly marketing & sales medical affairs mergers & acquisitions pfizer regulatory affairs roche thrombosis insight, analysis and views viewpoints: fda willing to keep a light on for mersana’s xmt-1522 (ref: viewpoints desk) published: 4 hours ago tags: viewpoints xmt-1522 xmt-1536 mersana therapeutics fda breast cancer lung cancer gynaecology/obstetrics pulmonary/respiratory medicine clinical research (r&d) regulatory affairs viewpoints: coherus back on track for neulasta biosimilar- again (ref: viewpoints desk) published: 17 hours ago tags: viewpoints chs-1701 neulasta amgen apotex coherus novartis marketing & sales regulatory affairs viewpoints: bristol-myers squibb back for more from ifm therapeutics (ref: viewpoints desk) published: 17 hours ago tags: viewpoints bms ifm therapeutics quest clinical research irritable bowel syndrome nonalcoholic steatohepatitis corporate affairs licensing trending kol views results: invokana may get boost from credence but benefit likely to be shared by sglt-2 class, says leading endocrinologist ptc therapeutics stock spikes on $200 million acquisition of agilis biotherapeutics viewpoints: bristol-myers squibb back for more from ifm therapeutics viewpoints: low expectations mean abicipar data do not disappoint sobi gains rights to novimmune's emapalumab for primary haemophagocytic lymphohistiocytosis glaxosmithkline mulls spinning off consumer division to form standalone company focused on drugs, vaccines: report according to people familiar with the matter, glaxosmithkline chairman philip hampton has been talking to the company's largest shareholders about the prospect of spinning off the consumer division... read more >> my news upgrade your subscription to get more features! conference news model offers efficient prediction of dvt with key clinical, d-dimer factors: presented at isth published: yesterday tags: conference dispatch thrombosis internal medicine isth siteone therapeutics to present research findings for selective small molecule nav1.7 inhibitors at the 2018 world congress on pain (ref: pr newswire) published: yesterday tags: press release siteone therapeutics pain management anesthesiology internal medicine clinical research (r&d) medical affairs world congress on pain united neuroscience announces presentation at the 2018 alzheimer's association international conference (aaic) (ref: pr newswire) published: yesterday tags: press release ub-311 united neuroscience dementia immunisation general practice internal medicine clinical research (r&d) medical affairs aaic latest news crinetics pharmaceuticals announces closing of initial public offering and exercise in full of the underwriters’ option to purchase additional shares (ref: globenewswire) published: 14 min ago tags: press release crinetics corporate affairs glaxosmithkline mulls spinning off consumer division to form standalone company focused on drugs, vaccines: report (ref: london south east, thestreet, investor's business daily, cnbc, the telegraph, yahoo!finance, financial times) published: 22 min ago tags: top story gsk corporate affairs drug now in clinical trials for parkinson’s strengthens heart contractions in animals (ref: johns hopkins medicine) published: 1 hour ago tags: press release iti-214 intra-cellular therapies parkinson's internal medicine clinical research (r&d) fda approves nivestym (filgrastim-aafi) a biosimilar to neupogen (filgrastim) (ref: fda) published: 1 hour ago tags: press release neupogen nivestym amgen pfizer fda marketing & sales regulatory affairs karo pharma triples sales and profit in the second quarter (ref: cision) published: 1 hour ago tags: press release karo bio corporate affairs storywatch crinetics pharmaceuticals announces closing of initial public offering and exercise in full of the underwriters’ option to purchase additional shares (ref: globenewswire) published: 14 min ago tags: press release crinetics corporate affairs fda approves nivestym (filgrastim-aafi) a biosimilar to neupogen (filgrastim) (ref: fda) published: 1 hour ago tags: press release neupogen nivestym amgen pfizer fda marketing & sales regulatory affairs poseida awarded $3.99 million cirm grant to support preclinical development of p-psma-101, a t stem cell memory car-t therapy for prostate cancer (ref: globenewswire) published: 2 hours ago tags: press release p-bcma-101 poseida therapeutics prostate cancer corporate affairs -- -- about firstword pharma | refer a colleague | upgrade your firstword pharma | contact firstword pharma | firstword reports advertise with firstword pharma | industry partner showcase all contents copyright © 2018 doctor's guide publishing limited. all rights reserved. terms of use | privacy policy

Analyse PopURL pour firstwordpharma.com

http://www.firstwordpharma.com/search/apachesolr_search/tid%3a37965?&s=tid%3a37965&tsid=28®ion_id=1
http://www.firstwordpharma.com/search/apachesolr_search/tid%3a55647?&s=tid%3a55647&tsid=28®ion_id=5
http://www.firstwordpharma.com/search/apachesolr_search/tid%3a49782?&s=tid%3a49782&tsid=28®ion_id=3
http://www.firstwordpharma.com/node/1580225?tsid=28®ion_id=3
http://www.firstwordpharma.com/node/1580225?tsid=28®ion_id=4
http://www.firstwordpharma.com/search/apachesolr_search/tid%3a36853?&s=tid%3a36853&tsid=28®ion_id=1
http://www.firstwordpharma.com/search/apachesolr_search/tid%3a7411?&s=tid%3a7411&tsid=28®ion_id=5
http://www.firstwordpharma.com/search/apachesolr_search/tid%3a25914?&s=tid%3a25914&tsid=28®ion_id=5
http://www.firstwordpharma.com/saved_content/add/1580201?tsid=28®ion_id=3
http://www.firstwordpharma.com/contactus?tsid=28
http://www.firstwordpharma.com/node/1579998?tsid=28®ion_id=2
http://www.firstwordpharma.com/search/apachesolr_search/tid%3a25962?&s=tid%3a25962&tsid=28®ion_id=1
http://www.firstwordpharma.com/search/apachesolr_search/tid%3a25962?&s=tid%3a25962&tsid=28®ion_id=4
http://www.firstwordpharma.com/search/apachesolr_search/tid%3a25962?&s=tid%3a25962&tsid=28®ion_id=5
http://www.firstwordpharma.com/search/apachesolr_search/tid%3a1560?&s=tid%3a1560&tsid=28®ion_id=3

Informations Whois

Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;

Domain Name: FIRSTWORDPHARMA.COM
Registry Domain ID: 246116116_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.networksolutions.com
Registrar URL: http://networksolutions.com
Updated Date: 2014-06-19T15:11:38Z
Creation Date: 2005-11-03T17:13:30Z
Registry Expiry Date: 2018-11-03T16:13:30Z
Registrar: Network Solutions, LLC.
Registrar IANA ID: 2
Registrar Abuse Contact Email: abuse@web.com
Registrar Abuse Contact Phone: +1.8003337680
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS1.P16.DYNECT.NET
Name Server: NS2.P16.DYNECT.NET
Name Server: NS3.P16.DYNECT.NET
Name Server: NS4.P16.DYNECT.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-11-27T16:26:25Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Network Solutions, LLC.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =firstwordpharma.com

  PORT 43

  TYPE domain
RegrInfo
DOMAIN

  NAME firstwordpharma.com

  CHANGED 2014-06-19

  CREATED 2005-11-03

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  NS1.P16.DYNECT.NET 208.78.70.16

  NS2.P16.DYNECT.NET 204.13.250.16

  NS3.P16.DYNECT.NET 208.78.71.16

  NS4.P16.DYNECT.NET 204.13.251.16

  REGISTERED yes

Go to top

firstwordpharma.com rapport : Visitez le site